1333466-55-9

Basic information

• Product Name: 4-N-(benzyl-5-acetyloxymethyl)cytosine
• Synonyms: 4-N-(benzyl-5-acetyloxymethyl)cytosine
• CAS NO: 1333466-55-9
• Molecular Weight: 273.291
• Mol File: 1333466-55-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-N-(benzyl-5-acetyloxymethyl)cytosine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-(benzyl-5-acetyloxymethyl)cytosine(1333466-55-9)
• EPA Substance Registry System: 4-N-(benzyl-5-acetyloxymethyl)cytosine(1333466-55-9)

Safety Data

• Hazardous Substances Data: 1333466-55-9(Hazardous Substances Data)

Upstream product

• 5785-16-0 N⁴-benzylcytosine 
• 1333466-54-8 4-N-(benzyl-5-hydroxymethyl)cytosine 
• 108-24-7 acetic anhydride 
• 1346635-30-0 C₁₁H₉N₃O 
• 100-52-7 benzaldehyde 

Relevant articles and documents

New cytosine derivatives as inhibitors of DNA methylation

DNA cytosine methylation catalyzed by DNA methyltransferase 1 (DNMT1) is an epigenetic method of gene expression regulation and development. Changes in methylation pattern lead to carcinogenesis. Inhibition of DNMT1 activity could be a good strategy of safe and efficient epigenetic therapy. In this work, we present a novel group of cytosine analogs as inhibitors of DNA methylation. We show new methods of synthesis and their effect on in vitro reaction of DNA methylation. Almost all of analyzed compounds inhibit DNA methyltransferase activity in the competitive manner. Ki values for the most potent compound 4-N-furfuryl-5,6-dihydroazacytosines is 0.7 μM. These compounds cause also a decrease of 5-methylcytosine (m5C) level in DNA of mammalian HeLa and HEK293 cells.

A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION

This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation. More precisely, the invention relates to various derivatives of cytosine, as well as methods of preparation of mono- and multi- 1,4,5 and 6-substituted cytosines. In general, the solution relates to providing effective modulators of DNA methylation which could be used in prevention and treatment of diseases associated with DNA methylation level disorders.